Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07419373 · ClinicalTrials.gov registry record · Phase 2
ARN-75039 Lassa Fever Treatment in West Africa
A Phase 2 study of Lassa Fever, sponsored by Arisan Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
- 4
- Study locations
NCT07419373: Recruiting Phase 2 study of Lassa Fever, sponsored by Arisan Therapeutics.
NCT07419373 is a Phase 2 study of Lassa Fever that is actively recruiting participants, run by Arisan Therapeutics. The registered enrollment target is 135 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07419373, a Phase 2 study of Lassa Fever, is actively recruiting participants, sponsored by Arisan Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
- 4
- Study locations
Study Summary
This multicenter, randomized, open-label Phase 2 clinical trial evaluates the safety, tolerability, and virologic efficacy of ARN-75039, a novel oral antiviral, for treating Lassa fever in hospitalized adults in West Africa. The study is conducted within the INTEGRATE platform and compares two oral dose regimens of ARN-75039 (100 mg BID and 50 mg BID) with intravenous ribavirin, the locally mandated standard of care. Approximately 135 participants with RT-PCR-confirmed Lassa virus infection will be enrolled and randomized 1:1:1 to receive ARN-75039 high dose, ARN-75039 low dose, or ribavirin for 10 days, followed by safety and efficacy follow-up through Day 28. The primary objectives are to assess safety and tolerability and to evaluate antiviral activity, as measured by the change in slope of Lassa virus RT-PCR cycle threshold (Ct) values from Day 1 to Day 10, in participants with low baseline viral load Ct values. Secondary objectives include additional virologic, pharmacokinetic, and clinical outcome assessments, including time to viral clearance, symptom resolution, organ failure, and mortality. ARN-75039 is a small-molecule viral entry inhibitor targeting the Lassa virus glycoprotein complex and has demonstrated potent antiviral activity and favorable safety and pharmacokinetic profiles in preclinical models and Phase 1 clinical studies. This study aims to inform dose selection and support further clinical development of ARN-75039 as a potential treatment for Lassa fever.
Conditions Studied
Interventions
- DRUG ARN-75039 high
- DRUG Intravenous ribavirin
- DRUG ARN-75039 low
Study Locations (4)
Other
- Abubakar Tafawa Balewa University Teaching Hospital - Bauchi
- Irrua Specialist Teaching Hospital - Irrua
California
- Arisan Therapeutics - Carlsbad
Ondo State
- Federal Medical Centre, Owo - Owo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2026-02 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
What NCT07419373 shows while recruiting
NCT07419373 is an interventional study that assigns participants to a tested intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Lassa Fever appearing as the primary indexed condition, and to 3 interventions - of which ARN-75039 high is the first listed.
NCT07419373 reports a single indexed study location in Other, California, Ondo State.
Frequently Asked Questions
What is clinical trial NCT07419373 about?
NCT07419373 is a clinical study titled "ARN-75039 Lassa Fever Treatment in West Africa". This multicenter, randomized, open-label Phase 2 clinical trial evaluates the safety, tolerability, and virologic efficacy of ARN-75039, a novel oral antiviral, for treating Lassa fever in hospitalized adults in West Africa. The study is conducted within the INTEGRATE platform and compares two oral ...
What is the current status of trial NCT07419373?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2026-02. Estimated completion is 2027-06.
What conditions does trial NCT07419373 study?
This clinical trial studies the following conditions: Lassa Fever.
What interventions are being tested in trial NCT07419373?
The interventions under investigation include: ARN-75039 high (DRUG), Intravenous ribavirin (DRUG), ARN-75039 low (DRUG).
Who is sponsoring clinical trial NCT07419373?
This trial is sponsored by Arisan Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07419373 being conducted?
This trial has 4 study locations across California, Ondo State. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lassa Fever
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07419373's enrollment target sits among peer trials
135 532nd of 2000 higher than 1,464 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia